Cargando…
Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery
Pentacyclic triterpenoids are well-known phytochemicals with various biological activities commonly found in plants as secondary metabolites. The wide range of biological activities exhibited by triterpenoids has made them the most valuable sources of pharmacological agents. A number of novel triter...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122576/ https://www.ncbi.nlm.nih.gov/pubmed/33918996 http://dx.doi.org/10.3390/molecules26092401 |
_version_ | 1783692655426797568 |
---|---|
author | Khwaza, Vuyolwethu Mlala, Sithenkosi Oyedeji, Opeoluwa O. Aderibigbe, Blessing A. |
author_facet | Khwaza, Vuyolwethu Mlala, Sithenkosi Oyedeji, Opeoluwa O. Aderibigbe, Blessing A. |
author_sort | Khwaza, Vuyolwethu |
collection | PubMed |
description | Pentacyclic triterpenoids are well-known phytochemicals with various biological activities commonly found in plants as secondary metabolites. The wide range of biological activities exhibited by triterpenoids has made them the most valuable sources of pharmacological agents. A number of novel triterpenoid derivatives with many skeletal modifications have been developed. The most important modifications are the formation of analogues or derivatives with nitrogen-containing heterocyclic scaffolds. The derivatives with nitrogen-containing heterocyclic compounds are among the most promising candidate for the development of novel therapeutic drugs. About 75% of FDA-approved drugs are nitrogen-containing heterocyclic moieties. The unique properties of heterocyclic compounds have encouraged many researchers to develop new triterpenoid analogous with pharmacological activities. In this review, we discuss recent advances of nitrogen-containing heterocyclic triterpenoids as potential therapeutic agents. This comprehensive review will assist medicinal chemists to understand new strategies that can result in the development of compounds with potential therapeutic efficacy. |
format | Online Article Text |
id | pubmed-8122576 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81225762021-05-16 Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery Khwaza, Vuyolwethu Mlala, Sithenkosi Oyedeji, Opeoluwa O. Aderibigbe, Blessing A. Molecules Review Pentacyclic triterpenoids are well-known phytochemicals with various biological activities commonly found in plants as secondary metabolites. The wide range of biological activities exhibited by triterpenoids has made them the most valuable sources of pharmacological agents. A number of novel triterpenoid derivatives with many skeletal modifications have been developed. The most important modifications are the formation of analogues or derivatives with nitrogen-containing heterocyclic scaffolds. The derivatives with nitrogen-containing heterocyclic compounds are among the most promising candidate for the development of novel therapeutic drugs. About 75% of FDA-approved drugs are nitrogen-containing heterocyclic moieties. The unique properties of heterocyclic compounds have encouraged many researchers to develop new triterpenoid analogous with pharmacological activities. In this review, we discuss recent advances of nitrogen-containing heterocyclic triterpenoids as potential therapeutic agents. This comprehensive review will assist medicinal chemists to understand new strategies that can result in the development of compounds with potential therapeutic efficacy. MDPI 2021-04-21 /pmc/articles/PMC8122576/ /pubmed/33918996 http://dx.doi.org/10.3390/molecules26092401 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Khwaza, Vuyolwethu Mlala, Sithenkosi Oyedeji, Opeoluwa O. Aderibigbe, Blessing A. Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery |
title | Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery |
title_full | Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery |
title_fullStr | Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery |
title_full_unstemmed | Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery |
title_short | Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery |
title_sort | pentacyclic triterpenoids with nitrogen-containing heterocyclic moiety, privileged hybrids in anticancer drug discovery |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122576/ https://www.ncbi.nlm.nih.gov/pubmed/33918996 http://dx.doi.org/10.3390/molecules26092401 |
work_keys_str_mv | AT khwazavuyolwethu pentacyclictriterpenoidswithnitrogencontainingheterocyclicmoietyprivilegedhybridsinanticancerdrugdiscovery AT mlalasithenkosi pentacyclictriterpenoidswithnitrogencontainingheterocyclicmoietyprivilegedhybridsinanticancerdrugdiscovery AT oyedejiopeoluwao pentacyclictriterpenoidswithnitrogencontainingheterocyclicmoietyprivilegedhybridsinanticancerdrugdiscovery AT aderibigbeblessinga pentacyclictriterpenoidswithnitrogencontainingheterocyclicmoietyprivilegedhybridsinanticancerdrugdiscovery |